Safety and Efficacy of Co-Administration of Sitagliptin and Metformin in China (MK-0431-121)

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 744 participants.

Also called NCT01076088

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 744 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT01076088
Other papers using this trial's data
  • Randomized clinical trial of the safety and efficacy of sitagliptin and metformin co-administered to Chinese patients with type 2 diabetes mellitus Journal of diabetes investigation, 2016-09 DOI, PubMed 27181998, PMC5009135 In the PMC Open Access subset under CC BY-NC.

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
Not reported
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01076088. Randomized; double masking; primary purpose treatment. Start 2010-11-15 (actual); primary completion 2012-12-24 (actual). Results posted on 2014-02-06.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Safety and Efficacy of Co-Administration of Sitagliptin and Metformin in China (MK-0431-121)
Condition
Type 2 Diabetes Mellitus
Intervention (Drug)
Sitagliptin 50 mg
Intervention (Drug)
Metformin 500 mg
Intervention (Drug)
Sitagliptin 100 mg
Intervention (Drug)
Placebo
Intervention (Drug)
Metformin 850 mg
Lead sponsor
Merck Sharp & Dohme LLC (class: industry)

Record details

Record id
cardio:ct-nct01076088
Content hash
f4fc9e45656b1899b2be930764263717def57f7e57f80a6bfdc2b97524a2a3cf